Charles M.
- Country
- France
- Department
- Nuclear Medicine
Research Overview
- Phase I/II Evaluation of 177Lu-PentixaTher Radioligand Therapy in Relapsed/Refractory CXCR4-Positive Acute Leukemia
- A pivotal phase 3 clinical trial to assess the diagnostic performance and safety of [68Ga]Ga-PentixaFor ([68Ga]Ga-PTF), a positron emission tomography (PET) imaging agent, versus [18F]FDG PET/CT imaging, for staging of patients with confirmed marginal zone lymphoma (MZL) exemplary for CXCR4-positive malignant lymphomas: a prospective, international, multi-center, comparative, randomized, cross-over, open-label lymphoma diagnostic trial (LYMFOR).
- Evaluation of [68Ga]Ga-PentixaFor PET for Initial Staging and Therapeutic Assessment in Symptomatic Multiple Myeloma Patients at Diagnosis or Relapse
Data & Insights
Has run more than one trial at 2 of 26 partner sites.
Specializations
Hematologic Oncology
This investigator specializes in the diagnosis and treatment of various hematological malignancies, with particular expertise in lymphoid neoplasms and blood cancers.
- Marginal Zone Lymphoma
- Multiple Myeloma
- Acute Leukemia
Their work encompasses both initial disease staging and therapeutic evaluation.
Nuclear Medicine Applications
The investigator focuses on advanced nuclear imaging techniques and radioligand therapy applications in blood cancers.
- PET/CT Imaging
- Radioligand Therapy
- Novel Radiopharmaceuticals
Their expertise includes the evaluation of novel imaging tracers for cancer detection and staging.
Diagnostic Innovation
The investigator develops and evaluates innovative diagnostic approaches for hematological conditions.
- Molecular Imaging
- Disease Staging Methods
- Treatment Response Assessment
Their work includes comparative analysis of different imaging modalities for optimal disease detection.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.